Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature

Vascular functions of PlGF remain poorly understood and controversial. Here, we show that tumor cell-derived PlGF-1 and PlGF-2 displayed significant remodeling effects on the tumor vasculature, leading to a normalized vascular phenotype and improved functions against leakage. In two murine tumor models, that is, T241 fibrosarcoma and Lewis lung carcinoma, stable expression of PlGF-1 and PlGF-2 in tumor cells resulted in significant reduction of tumor microvascular density and branch formation. Markedly, the vasculature in PlGF-expressing tumors consisted of relatively large-diameter microvessels with substantial improvement of pericyte coverage. Similarly, PlGF-induced vascular normalization and remodeling were also observed in a spontaneous human choriocarcinoma that expressed endogenous PlGF. Our findings shed light on functions of PlGF as a vascular remodeling factor that normalizes the tumor vasculature and thus may have conceptual implications of cancer therapy.

[1]  Yihai Cao,et al.  Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. , 2009, Seminars in cancer biology.

[2]  H. Augustin,et al.  Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. , 2009, The Journal of clinical investigation.

[3]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[4]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[5]  Yihai Cao.  Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands , 2009, Science Signaling.

[6]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[7]  A. Hansen,et al.  Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome , 2008, Proceedings of the National Academy of Sciences.

[8]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[9]  Antonio Duarte,et al.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation , 2008, Nature.

[10]  F. Peale,et al.  Blocking neuropilin-2 function inhibits tumor cell metastasis. , 2008, Cancer cell.

[11]  K. Becker,et al.  VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. , 2008, The Journal of clinical investigation.

[12]  Wen Shi,et al.  Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. , 2007, Cancer research.

[13]  G. Christofori,et al.  Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor-A–Dependent Tumor Angiogenesis during β Cell Carcinogenesis , 2007 .

[14]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[15]  R. Jain,et al.  αPlGF: A New Kid on the Antiangiogenesis Block , 2007, Cell.

[16]  P. Choyke,et al.  The biologic basis of in vivo angiogenesis imaging. , 2007, Frontiers in bioscience : a journal and virtual library.

[17]  Holger Gerhardt,et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.

[18]  Nathan D. Lawson,et al.  Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries , 2007, Nature.

[19]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[20]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[21]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[22]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[23]  D. McDonald,et al.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition. , 2006, The Journal of clinical investigation.

[24]  M. Shibuya.  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.

[25]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[26]  G. Neufeld,et al.  Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. , 2006, Blood.

[27]  Ricky T. Tong,et al.  Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. , 2006, Cancer research.

[28]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[29]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[30]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[31]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[32]  Toshio Ohhashi,et al.  PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. , 2004, Cancer cell.

[33]  Yihai Cao,et al.  Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion , 2004, Circulation research.

[34]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[35]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[36]  Rachel Jones.  Prefrontal cortex: One step at a time? , 2002, Nature Reviews Neuroscience.

[37]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[38]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[39]  Yihai Cao,et al.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. , 2002, Cancer Cell.

[40]  K. Alitalo,et al.  Vascular Endothelial Growth Factor-B–Deficient Mice Display an Atrial Conduction Defect , 2001, Circulation.

[41]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[42]  Xuri Li,et al.  Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. , 2001, The international journal of biochemistry & cell biology.

[43]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[44]  H. Dvorak,et al.  VPF/VEGF and the angiogenic response. , 2000, Seminars in perinatology.

[45]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[46]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[47]  Y. Cao,et al.  Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. , 1997, Biochemical and biophysical research communications.

[48]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[49]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[50]  T. Harris,et al.  Pulmonary vascular resistance distribution and recruitment of microvascular surface area. , 1994, Journal of applied physiology.

[51]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Arbiser,et al.  Regulation of gene expression in choriocarcinoma by methotrexate and hydroxyurea. , 1991, Endocrinology.

[53]  Yihai Cao.  Tumor angiogenesis and molecular targets for therapy. , 2009, Frontiers in bioscience.

[54]  Zhen-ping Zhu,et al.  Supplemental Data Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation , 2008 .

[55]  Franklin Peale,et al.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.

[56]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[57]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[58]  G. Christofori,et al.  Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. , 2007, Cancer research.

[59]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[60]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[61]  D. Maglione.  Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .